NCBiotech News

As we weigh the GSK layoff announcement, let’s be glad for what we have and celebrate what’s to come. Sure, things will never be the same. But the fact is, they never were anyway.

Patheon is adding 488 jobs to its Greenville facility by the end of 2019 as part of a planned $159 million expansion of the site.

The Biomanufacturing and Process Development (BPD) group is dedicated toward providing opportunities for the local bioprocessing group, professionals and students alike, to network, share information and discuss technical issues. As one of the many avenues to do so, we conduct an annual Facility Tour event.

Gene therapy pioneer AskBio of Chapel Hill, supported in its early years by NCBiotech, will be acquired by Bayer AG, the German healthcare and ag conglomerate, for up to $4 billion.

Amanda Taylor, a 29-year veteran of Merck, assumed responsibility for the Maurice R. Hilleman Center for Vaccine Manufacturing in Durham.on August 1.

The Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, where yet another 100-job expansion was announced this week, is key to Merck’s future as one of the world’s powerhouse vaccine manufacturers.

Grifols, a global biotherapeutics company, has begun Phase 3 clinical trials in patients with COVID-19 with its therapeutic manufactured in Clayton.

Global pharmaceutical giant Eli Lilly and Company will build its first North Carolina manufacturing facility in the Durham County portion of Research Triangle Park, investing $474 million and creating 462 new jobs.

San Diego-based Illumina, which founded GRAIL in 2016 and then spun it off as a standalone business, is now buying the unique cancer-testing company, with plans for a Durham factory, for $8 billion.

Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.

bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.

A young Boston-area gene therapy company, Beam Therapeutics, has joined a cluster of gene and cell therapy startups with plans to build an $83 million biomanufacturing facility in Durham that could employ more than 200 people over five years.

Grifols, a global biotherapeutics company with major operations in North Carolina, has delivered the first batches of a therapeutic product manufactured in Clayton that could help prevent and treat COVID-19 infection.

Medicago – with a biomanufacturing facility in Durham –  is using a form of tobacco to produce an experimental plant-based vaccine for COVID-19.

Fresenius Kabi, a global health care company based in Germany, hosted a topping off ceremony last week to celebrate the $100 million expansion of its pharmaceutical manufacturing campus in Wilson.